论文部分内容阅读
目的:探讨三阴性乳腺癌(TNBC)中ki-67的表达与新辅助化疗疗效分析。方法:收集来自于贵阳医学院附属医院乳腺外科2009年1月~2012年3月行新辅助化疗的乳腺癌病例共478例,其中三阴性乳腺癌病例84例,利用免疫组化技术检测ki-67,探讨ki-67在三阴性乳腺癌中的表达与新辅助化疗疗效作相关分析。结果:1、三阴性乳腺癌(TNBC)患者较非三阴性乳腺癌(N-TNBC)发病年龄早、组织学分级差、容易发生淋巴结转移、分期较晚。2、三阴性乳腺癌(TNBC)组的ki-67高增殖表达率为64.3%(54/84),在非三阴性乳腺癌(N-TNBC)组中表达为48.5%(191/394),差异具有统计学意义(P<0.05)。3、ki-67在TNBC患者行NAC疗效达pCR病例中的阳性表达率为79.1%,非pCR组中为34.2%,差异具有统计学意义(P<0.05)。
Objective: To investigate the expression of ki-67 in triple negative breast cancer (TNBC) and the effect of neoadjuvant chemotherapy. Methods: A total of 478 cases of breast cancer were collected from Department of Breast Surgery, Affiliated Hospital of Guiyang Medical College from January 2009 to March 2012, of which 84 cases were triple negative breast cancer. Immunohistochemistry was used to detect ki- 67, to investigate the expression of ki-67 in triple negative breast cancer and neoadjuvant chemotherapy efficacy correlation analysis. Compared with non-triple negative breast cancer (N-TNBC), triple negative breast cancer (TNBC) patients had earlier age of onset, poor histological grade, and lymph node metastasis. The expression rates of ki-67 in triple-negative breast cancer (TNBC) group were 64.3% (54/84), 48.5% (191/394) in non-triple negative breast cancer (N-TNBC) The difference was statistically significant (P <0.05). The positive rate of ki-67 expression in TNBC patients with NAC was 79.1% and 34.2% in non-pCR patients, respectively. The difference was statistically significant (P <0.05).